Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study

被引：0

作者：

Zoghbi, Marianne ^{[1
]}

Jabbour, Elias ^{[1
]}

Haddad, Fadi ^{[1
]}

Short, Nicholas James ^{[1
]}

Senapati, Jayastu ^{[1
]}

Macaron, Walid ^{[1
]}

Nasnas, Cedric Christophe ^{[1
]}

Nasr, Lewis Fady ^{[1
]}

Pemmaraju, Naveen ^{[1
]}

Jain, Nitin ^{[1
]}

Wierda, William G. ^{[1
]}

Borthakur, Gautam ^{[1
]}

Bravo, Guillermo Montalban ^{[1
]}

Ravandi, Farhad ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

Kadia, Tapan M. ^{[1
]}

Chien, Kelly Sharon ^{[1
]}

Thankachan, Jennifer ^{[1
]}

Garris, Rebecca ^{[1
]}

Kantarjian, Hagop M. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e19039

引用

页数：1

共 50 条

[21] A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia ChromosomePositive Acute Lymphoblastic Leukemia
Jen, Wei-Ying
Jabbour, Elias
Haddad, Fadi G.
Nasr, Lewis
Short, Nicholas J.
Zoghbi, Marianne
Nasnas, Cedric
Issa, Ghayas C.
Yilmaz, Musa
Daver, Naval
Pemmaraju, Naveen
Masarova, Lucia
Ravandi, Farhad
Jain, Nitin
Deen, Wuliamatu
Loiselle, Christopher
Waller, Lourdes
Banks, Glenda
Garris, Rebecca
Kantarjian, Hagop M.
BLOOD, 2023, 142
[22] Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
Ottmann, O. G.
Larson, R. A.
Kantarjian, H. M.
le Coutre, P. D.
Baccarani, M.
Hochhaus, A.
Kim, D. W.
Fan, X.
Novick, S.
Giles, F. J.
LEUKEMIA, 2013, 27 (06) : 1411 - 1413
[23] Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study
Haddad, Fadi
Jabbour, Elias
Short, Nicholas
Jain, Nitin
Huante, Emmanuel Almanza
Sasaki, Koji
Nasnas, Patrice
Ravandi, Farhad
Kebriaei, Partow
Huang, Xuelin
Konopleva, Marina
Garcia-Manero, Guillermo
Champlin, Richard E.
Kadia, Tapan M.
Takahashi, Koichi
Daver, Naval
Khoury, Joseph D.
Jorgensen, Jeffrey L.
Wang, Sa A.
Jacob, Jovitta
Garris, Rebecca
Kantarjian, Hagop
BLOOD, 2022, 140 : 11698 - 11701
[24] Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD, With or Without Blinatumomab, Is Highly Effective in Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage
Jabbour, Elias
Sasaki, Koji
Ravandi, Farhad
Huang, Xuelin
Short, Nicholas J.
Khouri, Maria
Kebriaei, Partow
Burger, Jan
Khoury, Joseph
Jorgensen, Jeffrey
Jain, Nitin
Konopleva, Marina
Garcia-Manero, Guillermo
Kadia, Tapan
Cortes, Jorge
Jacob, Jovitta
Montalbano, Kathryn
Garris, Rebecca
O'Brien, Susan
Kantarjian, Hagop M.
CANCER, 2018, 124 (20) : 4044 - 4055
[25] Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Short, Nicholas J.
Konopleva, Marina
Jabbour, Elias
Kadia, Tapan M.
Daver, Naval
Cook, Robin
Jain, Nitin
Ravandi, Farhad
BLOOD, 2020, 136
[26] Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia
Jabbour, Elias
Sasaki, Koji
Short, Nicholas J.
Ravandi, Farhad
Huang, Xuelin
Khoury, Joseph D.
Kanagal-Shamanna, Rashmi
Jorgensen, Jeffrey
Khouri, Issa F.
Kebriaei, Partow
Jain, Nitin
Alvarado, Yesid
Kadia, Tapan M.
Paul, Shilpa
Garcia-Manero, Guillermo
Dabaja, Bouthaina S.
Burger, Jan A.
DiNardo, Courtney D.
Daver, Naval A.
Montalban-Bravo, Guillermo
Yilmaz, Musa
Ohanian, Maro
Ferrajoli, Alessandra
Jacob, Jovitta
Rostykus, Meagan
Garris, Rebecca
O'Brien, Susan
Kantarjian, Hagop M.
CANCER, 2021, 127 (12) : 2025 - 2038
[27] An Observational Study of Patients with Philadelphia Chromosome-Negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US
Emadi, Ashkan
Salhotra, Amandeep
Yang, Jay
Akhtari, Mojtaba
Tuglus, Catherine A.
Chia, Victoria M.
Romanov, Vadim
BLOOD, 2017, 130
[28] Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Jabbour, Elias
Roberts, Kathryn G.
Sasaki, Koji
Zhao, Yaqi
Qu, Chunxu
Gu, Zhaohui
Jain, Nitin
Patel, Keyur P.
Ravandi, Farhad
Short, Nicholas J.
Garcia-Manero, Guillermo
Garris, Rebecca
Kornblau, Steven
Konopleva, Marina Y.
Mullighan, Charles G.
Kantarjian, Hagop M.
BLOOD, 2019, 134
[29] Retrospective Study Evaluating Hematological Remission Rates and Survival in Chinese Adults with Relapsed or Refractory (r/r) Philadelphia Chromosome Negative (Ph-) B-Precursor Acute Lymphoblastic Leukemia (ALL)
Ma, Jun
Liu, Ting
Jin, Jie
Hu, Jianda
Liu, Qifa
Wang, Jianxiang
Shen, Zhixiang
Du, Xin
Jiang, Bin
Meng, Xianhua
BLOOD, 2016, 128 (22)
[30] Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).
Macaron, Walid
Kantarjian, Hagop M.
Short, Nicholas James
Ravandi, Farhad
Jain, Nitin
Kadia, Tapan M.
Haddad, Fadi
Valero, Yesid Alvarado
Daver, Naval Guastad
Borthakur, Gautam
Dinardo, Courtney Denton
Konopleva, Marina
Wierda, William G.
Jacob, Jovitta
Roy, Edith
Loiselle, Christopher
Milton, Anna
Rivera, Juan
Garris, Rebecca
Jabbour, Elias
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →